Idorsia Pharmaceuticals

Commercial-stage biopharma

IDIA · SIX · Switzerland

Public Market Listing

IDIASIX

SIX primary exchange listing

Live quotes, historical charts, and market capitalization for Idorsia Pharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Aprocitentan(Tryvio)
Approved
Endothelin receptor (ETA/ETB, dual)Small molecule
Hypertension

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (2)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$73M—$119M$59Mreport ↗
View 1 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$152M$58M$91M—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$266M$123M$112M$135Mreport ↗

Idorsia reported 2025 revenue of $266.47M, up 107.6% YoY, with R&D spend of $122.99M, down 24.8% YoY. Cash and equivalents stood at $112.34M, while net income or loss was not disclosed; the quarterly net burn was $135.04M.

For 2026, management guided to QUVIVIQ sales of CHF 200M, non-GAAP operating expenses of approximately CHF 330M, and a non-GAAP operating loss of CHF 120M. Pipeline developments include an expected Q2 2026 Phase 2 readout for daridorexant in pediatric insomnia, FDA alignment on the registrational program for lucerastat in Fabry disease, and advancing immunology programs including a CCR6 antagonist in psoriasis. Key disclosed events include QUVIVIQ 2025 global net sales of CHF 134M, JERAYGO approvals in the EU, UK, Switzerland, and Canada, progressing partnership discussions for TRYVIO/JERAYGO, and a 2025 debt restructuring.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$128M$164M$117M$300Mreport ↗
2023-FY$169M$327M$172M$332Mreport ↗
2022-FY$102M$401M$158M$868Mreport ↗
2021-FY$38M$453M$111M$695Mreport ↗